MediciNova to initiate clinical trial of MN-001 (tipelukast) in IPF
MediciNova announced that following completion of an agreement with Penn State and IRB approval by Penn State Milton S. Hershey Medical Center, MediciNova will initiate a Phase 2 clinical trial of MN-001 (tipelukast) to treat moderate to severe idiopathic pulmonary fibrosis. October 09, 2015